CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

ERBB2 (HER2) activating mutation

Gene: ERBB2 · Type: mutation

Indications: Non-small cell lung cancer, Breast cancer

SensitivityResistanceCIViC Context

Linked CIViC Profile: ERBB2 MUTATION

Evidence Level Distribution

Level A: 2Level B: 2Level C: 1
LevelTypeDirectionSignificanceDiseaseDrugsRating
BPredictiveSupportsSensitivity/ResponseBreast CancerNeratinib4
APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab Deruxtecan4
APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaZongertinib4
CPredictiveSupportsSensitivity/ResponseBladder CarcinomaPlatinum Compound3
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPertuzumab,Trastuzumab2